CLASS II ONGOING Device recall · Reported 12 Mar 2025 · FDA Enforcement Report

Access Erythropoietin (EPO) recalled by Beckman Coulter

Beckman Coulter is recalling Access Erythropoietin (EPO), distributed in 20 states. The recall was initiated on 3 Feb 2025 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesCatalog A16364 UDI-DI 15099590201838 Lot 439363
Quantity recalled498 US; 1576 OUS

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1249-2025
FDA event ID
96255
Recalling firm
Beckman Coulter, Chaska, MN
Classification
Class II
Status
Ongoing
Recall initiated
3 Feb 2025
FDA classified
28 Feb 2025
Reported
12 Mar 2025
Type
Voluntary: Firm initiated
Customers notified by
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Reason category
Other Reasons

Timeline

3 Feb 2025Recall initiated by company
28 Feb 2025Classified by FDA+25 days
12 Mar 2025Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Affected lot (439363) exhibited a negative dose drop of -22% with native patient samples compared to alternate reagent lots. Patient samples tested with the affected lot may demonstrate repeatable falsely decreased results, which may lead to improper diagnosis or repeat testing.

Product as listed by the FDA

Access Erythropoietin (EPO), Catalog Number - A16364 a glycoprotein (~30,400 Daltons) produced primarily by the kidney, is the principal factor regulating red blood cell production (erythropoiesis) in mammals. Renal production of EPO is regulated by changes in oxygen availability. Under conditions of hypoxia, the level of EPO in the circulation increases and this leads to increased production of red blood cells.

Where it was distributed

Domestic distribution to AL AR AZ CA CT FL ID IL IN KS MA MI NC NE NJ NY OH OR PA TN TX UT WA WV. International distribution to Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, France, Germany, Hungary, India, Italy, Japan, Korea, Republic of, Netherlands, Philippines, Russian Federation, Saudi Arabia, Slovakia, Spain, United Kingdom of Great Britain and Northern Ireland

AlabamaArkansasArizonaCaliforniaConnecticutFloridaIllinoisKansasMassachusettsMichiganNorth CarolinaNebraskaNew JerseyNew YorkPennsylvaniaTennesseeTexasUtahWashingtonWest Virginia

Questions about this recall

Why was it recalled?

Affected lot (439363) exhibited a negative dose drop of -22% with native patient samples compared to alternate reagent lots. Patient samples tested with the affected lot may demonstrate repeatable falsely decreased results, which may lead to improper diagnosis or repeat testing.

Which lots are affected?

Catalog A16364 UDI-DI 15099590201838 Lot 439363

Where was it sold?

Domestic distribution to AL AR AZ CA CT FL ID IL IN KS MA MI NC NE NJ NY OH OR PA TN TX UT WA WV. International distribution to Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, France, Germany, Hungary, India, Italy, Japan, Korea, Republic of, Netherlands, Philippines, Russian Federation, Saudi Arabia, Slovakia, Spain, United Kingdom of Great Britain and Northern Ireland

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Beckman Coulter

All 334

Other Other Medical Devices recalls

All 13,778